Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare') (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ('DCx'), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment.
Article content
Article content
'We have taken careful steps to evaluate all aspects of our business to ensure continued value generation, and this out-licensing agreement with DCx for our discovery platforms enables us to further focus on our clinical portfolio and drive cost reductions while maintaining an economic interest in the platform technologies we have developed,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'We look forward to reporting initial data from our two ongoing Phase 1 clinical trials in the second half of 2025, and continue to evaluate partnering and strategic alternatives across our portfolio assets.'
Article content
Under the terms of the out-licensing agreement, Repare will receive upfront and near-term payments totaling $4 million, as well as a 9.99% common equity position in DCx (including certain dilution protection rights) and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low-single digit tiered sales royalties for the development of certain products by DCx. Additionally, DCx will retain approximately 20 of Repare's preclinical research employees. Repare has the right to appoint one nominee to the board of directors of DCx. In connection with the transaction, Repare out-licensed its clinically-validated SNIPRx platform and its early discovery-stage SNIPRx-surf and STEP 2 platforms, along with other intellectual property. The SNIPRx-surf platform identifies cell surface targets based on gene expression and protein features in tumors or cancer models, including by clinically relevant biomarkers and machine learning algorithm. The STEP 2 platform is a chemogenomic discovery platform, which uses CRISPR-enabled genetic screens with small molecule inhibitors to identify clinically relevant genetic lesions that are sensitive to small molecule inhibitors.
Article content
About Repare Therapeutics Inc.
Article content
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare has utilized its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Repare's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
Article content
DCx Biotherapeutics is a preclinical-stage discovery and translational company addressing key dependencies of cancer lesions by developing multi-modal synergistic-targeting therapeutics with improved efficacy and tolerability while minimizing resistance. DCx's MuSic™ platform is enabled through the integration of CRISPR-based high-throughput functional screening combined with deep bioinformatics in support of advancing a pipeline of immune-stimulatory precisiono0 antibody drug conjugates to improve therapeutic outcomes against genetically-defined cancers. Visit www.dcxbio.com to learn more.
Article content
Forward-Looking Statements
Article content
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: Repare's out-license of its discovery platform to DCx; the risk that Repare may not realize the potential benefits of the transaction with DCx; Repare's ability to drive cost reductions while maintaining an economic interest in its assets; the timing, progress and results of Repare's two ongoing Phase 1 clinical trials; and the receipt of milestone payments and royalties under the out-license agreement. These forward-looking statements are based on Repare's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Repare's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and changes in tariffs and trade policies, on Repare's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Repare's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause Repare's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in Repare's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025. Repare expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at .
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
SASKATOON, SK, Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000. Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000. The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025, and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025, in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
U of W physics prof makes chilling Canadian scientific breakthrough
A University of Winnipeg professor and his team broke a Canadian record while taking what might just be a big step that gets scientists closer to understanding the universe's makeup. Jeff Martin's research team recently broke the Canadian record — previously held by his same crew — for ultracold neutron production. The process takes extremely hot and difficult-to-control neutrons — extremely small subatomic particles — out of an atom's nucleus and cools them so they can be studied more precisely. SUPPLIED Dr. Jeff Martin with the particle accelerator. He and his team broke a Canadian particle physics record this summer – producing 900,000 ultracold neutrons with each proton pulse. The breakthrough in the volume produced could lead to advanced knowledge about the Big Bang-created universe. 'Currently a big problem in physics is we don't know why the universe has matter in it. We can't explain that. It seems like it should have an equal amount of antimatter, but we don't see any antimatter anywhere,' Martin explained. '(The experiment) should enable us to discover something about antimatter, why there isn't any antimatter… the thought is: maybe the neutron does violate symmetry in some way, and we've just never seen it before because we couldn't measure precisely enough.' Through the process of taking protons and smashing them into atomic nuclei, neutrons are released at a very high heat. By cooling them, the neutrons bounce off materials instead of moving through them and can be bottled and examined. 'We had lots of simulations that were telling us that we should be able to break (the record). But these experiments have a long history of you open the valve and nothing comes out,' Martin said. 'When you had an experiment like that where you open the valve and nothing comes out, usually the second and third tries are also like that until you really figure out what's going on. It just shows that we really understand what's going on in our experiments.' The team, including professors and students from across Canada, collaborates with international scientists from Japan and conduct the studies at the TRIUMF particle accelerator lab in Vancouver. Martin has been working on the experiments since 2008. In the next few months, the team hopes to pass safety inspections on its latest neutron refrigerator iteration, which will hopefully produce up to 50 million ultracold neutrons. The volume would surpass the current world record held by a research team based in Switzerland. Wednesdays What's next in arts, life and pop culture. 'Once we get there no one can touch us,' Martin said. The experiment has secondary effects, too; new technologies developed for the study, such as diamond-like carbon coatings and sensitive magnetic sensors, may have applications in medical and other fields. Martin said if the team can market the sensors to the right people, medical processes, including MRIs, can be greatly improved. 'Potentially, our magnetic technologies developed in Winnipeg also could be useful for medical applications,' he said. Nicole BuffieMultimedia producer Nicole Buffie is a reporter for the Free Press city desk. Born and bred in Winnipeg, Nicole graduated from Red River College's Creative Communications program in 2020 and worked as a reporter throughout Manitoba before joining the Free Press newsroom as a multimedia producer in 2023. Read more about Nicole. Every piece of reporting Nicole produces is reviewed by an editing team before it is posted online or published in print — part of the Free Press's tradition, since 1872, of producing reliable independent journalism. Read more about Free Press's history and mandate, and learn how our newsroom operates. Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber. Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
Feasibility without First Nations isn't feasible
Opinion Earlier this month, the governments of Ontario, Alberta and Saskatchewan signed an agreement to explore the 'feasibility of a new west-east pipeline to bring western oil and gas to southern Ontario refineries and ports.' In a news release, Alberta premier Danielle Smith said: 'By advancing a Canadian energy corridor from Alberta to Ontario, we are securing long-term energy access for families and businesses, creating thousands of jobs, and opening new doors for trade and investment, while strengthening our position as a global energy leader.' There's only one problem, and it's a big one: Manitoba Premier Wab Kinew didn't sign it. So much for feasibility. Since the federal government's passing of the One Canadian Economy Act (Bill C-5), which promises to expedite approvals for projects deemed 'in the national interest,' provinces have been rushing to position themselves with Prime Minister Mark Carney's cabinet in the hopes their regional initiatives and economic dreams will come true. Ontario has even passed its own version of the federal bill, in what is surely a move to speed up approval for the Ring of Fire critical mineral project despite Indigenous opposition. The challenge for all of this — if you can call it a challenge — has been Canada's legal requirement under Section 35 of the Constitution to attain 'free, prior, and informed consent' when it comes to including and respecting Indigenous and treaty rights. Simply put, few provinces have partnership agreements with First Nations to build economic projects and, for those that do, these were made after lengthy and costly court battles, negotiations, and conflict. The federal bill, Ontario's bill and the 'feasibility' agreement between Alberta, Saskatchewan and Ontario has no First Nations, Métis or Inuit approval. In other words, they are not worth much and are simply a cause for conflict. To be honest, development occurred much quicker when Canada was genocidal. Until the past five decades, Canada never had a legal duty to consult Indigenous peoples on the land, water, the economy, or frankly anything really — so, it didn't. Since the country's founding in 1867 (and arguably before that), Canadian legislators took Indigenous and treaty land, moved people whenever and wherever, and made unilateral decisions on Indigenous lives and families all the time. When law got in the way, other laws were passed under the justification that Canada's national interests were paramount. This meant that swaths of Indian reserve lands were taken whenever a company, corporation, or the military wanted. Or, that masses of Indigenous leaders were imprisoned, Indigenous women were stripped of rights, and children were taken. All this happened blatantly. A few kilometres from where Winnipeggers sit was the St. Peter's Indian Band, whose lands in and around Selkirk were taken illegally in 1907 while the community was removed to what is now Peguis Indian Reserve. The tide started to change in the 1970s, when Canada's Supreme Court recognized that Indigenous title (and therefore law, government, and rights) existed and Canada had to start to act justly, humanely, and with consideration of their humanity. Things were supposed to be different — but old Canadian habits die hard. From the One Canadian Economy Act to the actions of provincial premiers, Canadian leaders continue to act as if Indigenous peoples are an afterthought, using age-old arguments that Canada's 'national interests' are paramount. That is, until Kinew — who has not shied away from interest in lucrative land and resource projects — refused to join his provincial counterparts. 'In other parts of the country with other levels of government, there's the commitment to maybe push things through with legislation first,' Kinew told media, explaining his decision. 'That puts other partners on the back foot.' Don't be confused. When Kinew says 'other partners,' he means First Nations, Inuit, and Métis rights holders. What the premier is doing isn't because he's First Nations, it's because he's trying to follow Canadian law. History has proven it's a tremendous waste of time, money, and energy to exclude Indigenous rights holders from conversations surrounding land, resources, and, frankly, the country. The first and most important 'project in the national interest' is to include Indigenous governments at the outset of every single decision this country makes. Anything else is illegal. An unprecedented step however requires an unprecedented idea. For Kinew, it's a Crown corporation (on par with entities such Manitoba Hydro and Manitoba Public Insurance) that can assemble Indigenous leadership to review and give approval of economic land and resource projects alongside provincial regulators. This 'Crown Indigenous corporation' would require buy-in and unity from Indigenous leadership — and seems to have almost immediately gained it. This week, the Southern Chiefs' Organization and the Manitoba Métis Federation came to an agreement to collectively 'advance economic reconciliation, protect Indigenous rights, and collaborate on major infrastructure and development projects across Manitoba.' That's no coincidence. That's First Nations and Métis holders on the front foot and reserving their spot at the table. Niigaan SinclairColumnist Niigaan Sinclair is Anishinaabe and is a columnist at the Winnipeg Free Press. Read full biography Our newsroom depends on a growing audience of readers to power our journalism. If you are not a paid reader, please consider becoming a subscriber. Our newsroom depends on its audience of readers to power our journalism. Thank you for your support.
